Extensive knowledge of healthcare systems built on a broad portfolio of opioid-related work with multiple federal and state agencies, including the CDC, SAMHSA, HHS and others.
Implementation studies of health and workforce development initiatives and programs that document best practices and lessons for both policymakers and program administrators.
Effective technical assistance to multiple programs and agencies to track service delivery options in SUD and opioid use disorder (OUD) treatment and recovery.
Creative and innovative approaches to evaluation design, including quasi- experimental evaluation, randomized controlled trials, predictive analytics and more to identify effective programs and services.
Demonstration research projects and pilot tests to measure the impact on providers and their patients of various opioid prescription policies and guidelines.
Collaboration with practitioners and policymakers to ensure that results are relevant and widely disseminated to stakeholders and targeted audiences in the field.
As a subcontractor to MDRC, Abt plays a lead role on the Building Evidence on Employment Strategies for Low-Income Families Study (BEES), a project sponsored by ACF at the U.S. Department of Health and Human Services. The goal is to conduct rigorous evaluations of innovative programs that increase employment and earnings of low-income families, especially those with substance use or mental disorders. Abt leads work on identifying and evaluating programs that blend employment and SUD recovery and treatment services.
Abt provided research and other support for development of the 2016 CDC guideline for prescribing opioids for non- cancer chronic pain outside end-of-life care settings. Abt performed rapid literature reviews, screened studies to identify those meeting research design criteria, synthesized the findings, and provided editorial support for draft clinical recommendations.
In several separately funded projects, Abt and our partners support implementation of the CDC Guideline for Prescribing Opioids for Chronic Pain in primary-care practices. As part of those projects, Abt has developed and evaluated several resources for clinicians and systems, including a quality improvement implementation guide and 16 opioid quality improvement (QI) measures that reflect guideline recommendations. Additionally, Abt is supporting a CDC-funded Opioid QI Collaborative of 12 large health systems to implement select recommendations and associated QI measures. Finally, Abt is developing clinical decision support tools embedded in electronic health records to assist clinicians at the point of care in following the CDC guideline recommendations at the point of care.
The CDC hired Abt to develop a coordinated care plan for safe opioid prescribing. This included upper-limit dosing thresholds, attention to drug-drug and drug-disease interactions, urine testing for drugs and use of medication- assisted treatment. With MedStar Health, we evaluated the demonstration sites’ ability to implement the plan’s practices. The guide and other resources are part of the CDC strategy for improving opioid prescription practices.
Abt supported the development of the first Surgeon General’s Report on Alcohol, Drugs, and Health, a seminal project that details the evidence-base behind MAT, effective MAT programs, and details the medications that have been approved to treat opioid use disorders. This Report will have major implications for how the U.S. addresses not only opioid misuse but also public health problems associated with alcohol and other substances.
Abt and its partner the Legal Action Center developed the “Know Your Rights” brochure and webinars to train and educate the public and those in recovery about the rights of individuals in recovery from alcohol or drug problems under federal and state laws. The information covers laws prohibiting discrimination against people with disabilities in the areas of employment, housing, public accommodation, and government benefits and services. It also covers the rights of individuals with criminal conviction histories and individuals in medication-assisted treatment.
On behalf of SAMHSA, Abt leads the Program Evaluation for Prevention Contract (PEP-C) to evaluate the Strategic Prevention Framework for Prescription Drugs (SPF-Rx). The SPF-Rx program empowers grantees to use the resources of stakeholders from public health departments to the pharmaceutical industry to reduce prescription drug and illicit opioid misuse and abuse among youth and adults.
Under its Behavioral Health Information Technology Strategy contract, Abt supported SAMHSA in launching technology challenges to spur developers to create solutions that provide additional recovery support to patients receiving outpatient medication-assisted treatment for opioid use disorder. One app developed can be part of a comprehensive treatment plan that supports access to resources, educational materials, and support for people in outpatient recovery from OUD.
Abt helped SAMHSA develop a text messaging library to support individuals with OUDs. Abt conducted stakeholder interviews with SAMHSA grantees who expressed interest in using text messaging services. We also interviewed subject matter experts with direct experience developing and implementing text messaging libraries and technology- based services for the behavioral health community.
Abt developed and tested 150 text messages targeted to individuals in various stages of recovery.
Abt Associates uses data and bold thinking to improve the quality of people’s lives worldwide. From increasing crop yields and combatting infectious disease, to ensuring safe drinking water and promoting access to affordable housing—and more—we partner with clients and communities to tackle their most complex challenges.